Abstract
Sudden cardiac death (SCD) is a serious public health problem; the annual incidence of out-of-hospital cardiac arrest in North America is approximately 166,200. Identifying patients at risk is a difficult proposition. At the present time, left ventricular ejection fraction (LVEF) remains the single most important marker for risk stratification. According to current guidelines, most patients with LVEF < 35% could benefit from prophylactic ICD implantation, particularly in the setting of symptomatic heart failure. Current risk stratification strategies fail to identify patients at risk of SCD in larger population groups encompassing a greater number of potential SCD victims. However, the best approach to identifying patients and the value of various risk stratification tools is not entirely clear. The goal of this review is to discuss the problem of SCD and the value of the different risk stratification markers and their potential clinical use either alone or in combination with other risk stratification markers.
Keywords: Sudden cardiac death, risk stratification markers
Current Cardiology Reviews
Title: Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Volume: 5 Issue: 1
Author(s): Gustavo Lopera and Anne B. Curtis
Affiliation:
Keywords: Sudden cardiac death, risk stratification markers
Abstract: Sudden cardiac death (SCD) is a serious public health problem; the annual incidence of out-of-hospital cardiac arrest in North America is approximately 166,200. Identifying patients at risk is a difficult proposition. At the present time, left ventricular ejection fraction (LVEF) remains the single most important marker for risk stratification. According to current guidelines, most patients with LVEF < 35% could benefit from prophylactic ICD implantation, particularly in the setting of symptomatic heart failure. Current risk stratification strategies fail to identify patients at risk of SCD in larger population groups encompassing a greater number of potential SCD victims. However, the best approach to identifying patients and the value of various risk stratification tools is not entirely clear. The goal of this review is to discuss the problem of SCD and the value of the different risk stratification markers and their potential clinical use either alone or in combination with other risk stratification markers.
Export Options
About this article
Cite this article as:
Lopera Gustavo and Curtis B. Anne, Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value, Current Cardiology Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157340309787048130
DOI https://dx.doi.org/10.2174/157340309787048130 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |
Call for Papers in Thematic Issues
Advances in Managing Cardiogenic Shock and the Value of Percutaneous Mechanical Circulatory Support
Despite the advances in cardiology, the outcomes of patients with cardiogenic shock remain poor. There is an increasing interest and use of mechanical circulatory support for patients with cardiogenic shock. Additionally, the complexity of coronary interventions has increased during the last decade with the potential of treating more high-risk patients ...read more
Artificial Intelligence (AI) in Cardiovascular Disease
Artificial Intelligence (AI) in cardiovascular disease is an emerging interdisciplinary field that integrates advanced technologies to improve patient care. The current AI landscape faces significant challenges, including the complexity of diagnosing and treating these conditions. Recent studies have shown promising results in the use of AI for early detection, diagnosis, ...read more
Chronic Disease Self-Management for Heart Failure – A Mini Review into Performance Gaps
Chronic disease self-management (CDSM) is a vital component of chronic disease management. There remain several important deficits in this concept. Its benefit are clear, many chronic diseases such as hypertension, diabetes, asthma, rheumatology syndromes have shown benefit in quality of life and quantitative measures of outcomes. Yet, in congestive heart ...read more
The Era of Cardiac Medication and Implantable Devices Therapy in Heart Failure Treatment Continues
The heart failure (HF) remains a serious public health problem and affects 64 million people worldwide. Although advances in medical therapy and device assistance have significantly improved HF outcomes, the implications of HF are still dramatic. In recent years, innovative developments have been made in HF treatment management, based on ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases
Current Rheumatology Reviews Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Editorial [Hot Topic: Perspectives of New Antihypertensive Drugs (Executive Editor: Ji-Guang Wang)]
Current Pharmaceutical Design Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Preface: Facing New Challenges in Cardiovascular Disease, When the Pressure Goes Up and the Pump Goes Astray
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design WITHDRAWN: Intermedin 1-53 Ameliorates Atrial Fibrosis and Reduces Inducibility of Atrial Fibrillation via TGF-β1/pSmad3 and Nox4 Pathways in a Rat Model of Heart Failure
Current Signal Transduction Therapy Emerging Therapy for Diabetic Neuropathy: Cell Therapy Targeting Vessels and Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipid Management and Peripheral Arterial Disease
Current Drug Targets Emerging Role of NF-κB in the Pathogenesis of Hepatic Encephalopathy
Current Signal Transduction Therapy New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Genetic and Non-Genetic Determinants of the Pharmacological Activity of Statins
Current Drug Metabolism Diuretics in the Treatment of Elderly Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients
Current Pharmaceutical Biotechnology The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews Progress in Therapies for Myocardial Ischemia Reperfusion Injury
Current Drug Targets Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry